MedPath

Myo-inositol and Melatonin in Pre-menopausal Women

Phase 2
Completed
Conditions
Pre-menopausal Irregular Cycles and Bleedings
Interventions
Dietary Supplement: melatonin plus myo-inositol
Dietary Supplement: myo-inositol
Dietary Supplement: melatonin
Registration Number
NCT01115127
Lead Sponsor
University of Messina
Brief Summary

The purpose of this study is to determine whether myo-inositol and melatonin, or myo-inositol alone, or melatonin alone, are effective in normalizing irregular bleeding and anovulatory cycles in pre-menopausal women.

Detailed Description

Melatonin has produced a remarkable significant improvement of thyroid function, positive changes of gonadotropins towards reduced levels, and in some women a re-acquisition of normal menstrual cycle. Furthermore, an abrogation of menopause-related depression, amelioration of hot-flashes and improvement of quality and duration of sleep has been reported.

Myo-inositol is involved in several aspects of human reproduction. Elevated concentrations of myo-inositol in human follicular fluids appear to play a positive function in follicular maturity and provide a marker of good quality oocytes. Nevertheless its positive role in PCOS women is a consequence of a defect in the insulin signalling pathway (inositol-containing phosphoglycan mediators) that seems to be primarily implicated in the pathogenesis of insulin resistance

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
90
Inclusion Criteria
  • all pre-menopausal women with irregular cycles and bleedings
Exclusion Criteria
  • pre-menopausal women who take hormonal drugs

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
melatonin plus myo-inositolmelatonin plus myo-inositol30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
myo-inositolmyo-inositol30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
melatoninmelatonin30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
Primary Outcome Measures
NameTimeMethod
Normalizing irregular bleeding and anovulatory cycles in pre-menopausal women.12 months
Secondary Outcome Measures
NameTimeMethod
Evaluation of metabolic markers (insulin, glucose, total cholesterol, HDL-cholesterol, triglycerides).12 months
Serum assays of thyroid hormones.12 months
Assays of gonadotropins and estradiol serum levels12 months
Variation of blood pressure.12 months
Variation of mood, hot flashes, quality of sleep.12 months

Trial Locations

Locations (1)

University Hospital

🇮🇹

Messina, Italy

© Copyright 2025. All Rights Reserved by MedPath